相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A mathematical model to predict nanomedicine pharmacokinetics and tumor delivery
Prashant Dogra et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2020)
Image-guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies
Prashant Dogra et al.
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY (2020)
Dendrimers toward Translational Nanotherapeutics: Concise Key Step Analysis
Serge Mignani et al.
BIOCONJUGATE CHEMISTRY (2020)
A Critical and Concise Review of Mass Spectrometry Applied to Imaging in Drug Discovery
Richard J. A. Goodwin et al.
SLAS DISCOVERY (2020)
AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia
Srividya B. Balachander et al.
CLINICAL CANCER RESEARCH (2020)
Report of the AAPS Guidance Forum on the FDA Draft Guidance for Industry: Drug Products, Including Biological Products, that Contain Nanomaterials
Jon S. B. de Vlieger et al.
AAPS JOURNAL (2019)
Mathematical modeling in cancer nanomedicine: a review
Prashant Dogra et al.
BIOMEDICAL MICRODEVICES (2019)
Quantifying the relationship between inhibition of VEGF receptor 2, drug-induced blood pressure elevation and hypertension
Teresa Collins et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
Establishing the effects of mesoporous silica nanoparticle properties on in vivo disposition using imaging-based pharmacokinetics
Prashant Dogra et al.
NATURE COMMUNICATIONS (2018)
Mass spectrometry imaging of the in situ drug release from nanocarriers
Jinjuan Xue et al.
SCIENCE ADVANCES (2018)
Why do BCL-2 inhibitors work and where should we use them in the clinic?
Joan Montero et al.
CELL DEATH AND DIFFERENTIATION (2018)
The BCL-2 arbiters of apoptosis and their growing role as cancer targets
Jerry M. Adams et al.
CELL DEATH AND DIFFERENTIATION (2018)
Tumour regression and improved gastrointestinal tolerability from controlled release of SN-38 from novel polyoxazoline-modified dendrimers
Richard M. England et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Comprehensive study of the drug delivery properties of poly(L-lactide)-poly (ethylene glycol) nanoparticles in rats and tumor-bearing mice
Vladimir Shalgunov et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles
Nicolas Floc'h et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Overview of the Use of Murine Models in Leukemia and Lymphoma Research
Rebecca Kohnken et al.
FRONTIERS IN ONCOLOGY (2017)
Cancer nanomedicine: progress, challenges and opportunities
Jinjun Shi et al.
NATURE REVIEWS CANCER (2017)
Cancer nanomedicine: a review of recent success in drug delivery
Stephanie Tran et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2017)
A Bottom-Up Whole-Body Physiologically Based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate of Subcutaneous Absorption of Therapeutic Proteins
Katherine L. Gill et al.
AAPS JOURNAL (2016)
Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo
Susan Ashton et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Nanoparticles in the clinic
Aaron C. Anselmo et al.
BIOENGINEERING & TRANSLATIONAL MEDICINE (2016)
Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity
Hiroshi Maeda
ADVANCED DRUG DELIVERY REVIEWS (2015)
NBCD Pharmacokinetics and Bioanalytical Methods to Measure Drug Release
Vishakha V. Ambardekar et al.
NON-BIOLOGICAL COMPLEX DRUGS: THE SCIENCE AND THE REGULATORY LANDSCAPE (2015)
Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: A concise overview
Serge Mignani et al.
ADVANCED DRUG DELIVERY REVIEWS (2013)
Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology
Uma Prabhakar et al.
CANCER RESEARCH (2013)
A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions
Lorna Ewart et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2013)
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
Andrew W. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Animal welfare and the 3Rs in European biomedical research
Dominic J. Wells
ANIMAL MODELS: THEIR VALUE IN PREDICTING DRUG EFFICACY AND TOXICITY (2011)
Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties
Lisa M. Kaminskas et al.
NANOMEDICINE (2011)
Physiologically Based Pharmacokinetic Modeling of Nanoparticles
Mingguang Lu et al.
ACS NANO (2010)
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wyndham H. Wilson et al.
LANCET ONCOLOGY (2010)
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
Mark S. Cragg et al.
NATURE REVIEWS CANCER (2009)
The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly L-lysine dendrimers
Lisa M. Kaminskas et al.
MOLECULAR PHARMACEUTICS (2008)
Programmed anuclear cell death delimits platelet life span
Kylie D. Mason et al.
CELL (2007)
Dendrimers and dendritic polymers in drug delivery
ER Gillies et al.
DRUG DISCOVERY TODAY (2005)
分享论文
